Inhibitors targeting the histone methyltransferases DOT1L and EZH2, as well as the demethylase KDM1 (also known as LSD1), have recently entered the first stages of clinical trials in cancer therapy and might hold the potential to modulate the cancer-immune system axis [16]. Here, DOT1L is linked to cancer.